R
Reinier Raymakers
Researcher at Utrecht University
Publications - 125
Citations - 5596
Reinier Raymakers is an academic researcher from Utrecht University. The author has contributed to research in topics: Multiple myeloma & Transplantation. The author has an hindex of 34, co-authored 123 publications receiving 5032 citations. Previous affiliations of Reinier Raymakers include Philips & Radboud University Nijmegen.
Papers
More filters
Journal ArticleDOI
Acquired mutations in TET2 are common in myelodysplastic syndromes
Saskia Langemeijer,Roland P. Kuiper,Marieke Berends,Ruth Knops,Mariam G Aslanyan,Marion Massop,Ellen Stevens-Linders,Patricia van Hoogen,Ad Geurts van Kessel,Reinier Raymakers,Eveline J. Kamping,Gregor Verhoef,E Verburgh,Anne Hagemeijer,Peter Vandenberghe,Theo de Witte,Bert A. van der Reijden,Joop H. Jansen +17 more
TL;DR: It is concluded that TET2 is the most frequently mutated gene in MDS known so far, and expression was shown to be elevated in hematopoietic cells with highest expression in granulocytes, in line with a function in myelopoiesis.
Journal ArticleDOI
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
Pieter Sonneveld,Ingo G.H. Schmidt-Wolf,Bronno van der Holt,Laila el Jarari,Uta Bertsch,Hans Salwender,Sonja Zweegman,Edo Vellenga,Annemiek Broyl,Igor Wolfgang Blau,Katja Weisel,Shulamiet Wittebol,Gerard M. J. Bos,Marian Stevens-Kroef,Christof Scheid,Michael Pfreundschuh,Dirk Hose,Anna Jauch,Helgi Van Der Velde,Reinier Raymakers,Martijn R. Schaafsma,Marie-Jose Kersten,Marinus van Marwijk-Kooy,Ulrich Duehrsen,Walter Lindemann,Pierre W. Wijermans,Henk M. Lokhorst,Hartmut Goldschmidt +27 more
TL;DR: Bortezomib during induction and maintenance improves CR and achieves superior PFS and OS and a benefit was also observed in patients with deletion 17p13.
Journal ArticleDOI
Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review.
Josien C. Regelink,Monique C. Minnema,Evangelos Terpos,Marjolein H. Kamphuis,Pieter G. Raijmakers,Indra C. Pieters – van den Bos,Ben G. F. Heggelman,Rutger-Jan Nievelstein,René H. J. Otten,Danielle van Lammeren – Venema,Josée M. Zijlstra,Anne I.J. Arens,Jacky W. J. de Rooy,Otto S. Hoekstra,Reinier Raymakers,Pieter Sonneveld,Raymond W. J. G. Ostelo,Sonja Zweegman +17 more
TL;DR: This systematic review supports the International Myeloma Working Group guidelines, which recommend that WBCT can replace WBXR, and indicates that the equal performance of MRI also indicates that it is a valuable alternative.
Journal ArticleDOI
Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a retrospective, pharmacodynamic cohort analysis
Rick Admiraal,Rick Admiraal,Stefan Nierkens,Moniek de Witte,Eefke Petersen,Ger-jan Fleurke,Luka Verrest,Svetlana V. Belitser,Robbert G. M. Bredius,Reinier Raymakers,Catherijne A. J. Knibbe,Monique C. Minnema,Charlotte van Kesteren,Jürgen Kuball,Jaap Jan Boelens +14 more
TL;DR: Exposure to ATG affects survival after HCT in adults, stressing the importance of optimum ATG dosing, and individualised dosing of ATG, based on lymphocyte counts rather than bodyweight, might improve survival chances after H CT.
Journal ArticleDOI
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial
H. Goldschmidt,Henk M. Lokhorst,Elias K. Mai,B. van der Holt,Igor Wolfgang Blau,Sonja Zweegman,Katja Weisel,Edo Vellenga,Michael Pfreundschuh,Marie-Jose Kersten,Christoph Scheid,Sandra Croockewit,Reinier Raymakers,Dirk Hose,Anna Potamianou,Anna Jauch,Jens Hillengass,Marian Stevens-Kroef,Marc-Steffen Raab,Annemiek Broijl,Hans-Walter Lindemann,Gerard M. J. Bos,Peter Brossart,M. van Marwijk Kooy,Paula F. Ypma,Ulrich Duehrsen,R. Schaafsma,Uta Bertsch,Thomas Hielscher,Le Jarari,H Salwender,Pieter Sonneveld +31 more
TL;DR: The survival benefit with BTZ induction/maintenance compared with classical cytotoxic agents and thalidomide maintenance is maintained without an increased risk of SPM.